Pricing and market entry decisions in personalized medicine

被引:3
作者
Luetkemeyer, Daniel [1 ]
Heese, H. Sebastian [2 ]
Wuttke, David A. [3 ]
Gernert, Andreas K. [4 ]
机构
[1] EBS Univ, EBS Business Sch, Burgstr 5, D-65375 Oestrich Winkel, Germany
[2] North Carolina State Univ, Poole Coll Management, 2801 Founders Dr, Raleigh, NC 27695 USA
[3] Tech Univ Munich, TUM Sch Management, TUM Campus Heilbronn,Bldg Campus 9, D-74076 Heilbronn, Germany
[4] Kuhne Logist Univ, Grossler Grasbrook 7, D-20457 Hamburg, Germany
关键词
Personalized medicine; New product development; Competition; Game theory; RESEARCH-AND-DEVELOPMENT; CO-DEVELOPMENT; SUPPLIER INTEGRATION; PRODUCT DEVELOPMENT; OPTIONS; IMPACT; MANUFACTURERS; DIAGNOSTICS; DRUG; GAME;
D O I
10.1016/j.ijpe.2022.108584
中图分类号
T [工业技术];
学科分类号
08 ;
摘要
In the pharmaceutical industry, personalized medicine is increasingly replacing the traditional blockbuster drug concept. Personalized medicine consists of a targeted drug that is only prescribed if a companion diagnostic test detects the corresponding biomarker. This concept promises improved treatments of various diseases. However, personalized medicine also presents pharmaceutical firms with new challenges resulting from interdependencies in the drug and diagnostic test development processes. Although pharmaceutical firms generally benefit from competition among diagnostic firms, the threat of substitutes from competitors could cause diagnostic firms to step back from new product development in the first place, leading to lost revenues for the pharmaceutical firm. We consider a pharmaceutical firm that may inform two competing differentiated diagnostic firms about a drug under development, such that these firms can develop a corresponding diagnostic test. We show which diagnostic firm the pharmaceutical firm should inform first and how granting early exclusivity to a single diagnostic firm can maximize pharmaceutical profits from personalized medicine.
引用
收藏
页数:17
相关论文
共 59 条
[1]   The current and future state of companion diagnostics [J].
Agarwal, Amit ;
Ressler, Dan ;
Snyder, Glenn .
PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2015, 8 :99-110
[2]  
Alvisi M., 2009, 200910 AMST CTR LAW
[3]   IMPERFECT SUBSTITUTES FOR PERFECT COMPLEMENTS: SOLVING THE ANTICOMMONS PROBLEM [J].
Alvisi, Matteo ;
Carbonara, Emanuela .
BULLETIN OF ECONOMIC RESEARCH, 2013, 65 (03) :256-279
[4]  
Amgen, 2017, FDA APPR VECT PAN US
[5]   Cooperative R&D and firm performance [J].
Belderbos, R ;
Carree, M ;
Lokshin, B .
RESEARCH POLICY, 2004, 33 (10) :1477-1492
[6]   Effort, Revenue, and Cost Sharing Mechanisms for Collaborative New Product Development [J].
Bhaskaran, Sreekumar R. ;
Krishnan, V. .
MANAGEMENT SCIENCE, 2009, 55 (07) :1152-1169
[7]   A Comparison of Milestone-Based and Buyout Options Contracts for Coordinating R&D Partnerships [J].
Bhattacharya, Shantanu ;
Gaba, Vibha ;
Hasija, Sameer .
MANAGEMENT SCIENCE, 2015, 61 (05) :963-978
[8]   Aligning the Economic Value of Companion Diagnostics and Stratified Medicines [J].
Blair, Edward D. ;
Stratton, Elyse K. ;
Kaufmann, Martina .
JOURNAL OF PERSONALIZED MEDICINE, 2012, 2 (04) :257-266
[9]  
Carlson Bob, 2012, Biotechnol Healthc, V9, P20
[10]   Evaluating the effects of quality regulations on the pharmaceutical supply chain [J].
Chen, Xu ;
Li, Shanshan ;
Wang, Xiaojun .
INTERNATIONAL JOURNAL OF PRODUCTION ECONOMICS, 2020, 230